Following news that the FDA has finalized its guidance on interchangeable biosimilars;
Rose Joachim, PhD Senior Immunology Pharma Analyst at GlobalData, a data and analytics company, offers her view on the implications for Immunology;
‘’The FDA’s new guidance is a huge step forward, however the new specifications will still make it a hard road ahead for biosimilar producers looking to make headway in the US.‘’
The FDA has specified that it does not consider post-marketing or other single-switch studies sufficient to prove the interchangeability of the product, requiring manufacturers to conduct new multi-switch studies. To date, only two large-scale studies in the immunology disease space have been conducted in this manner-one for Sandoz’s Erelzi and another for Sandoz’s Hyrimoz- both for the treatment of plaque psoriasis.
‘’Another factor that continues to complicate the utility of an interchangeability status on a biosimilar is the product’s pricing. Based on GlobalData’s analysis, in 2018 biosimilars commanded only 6% of the US infliximab market for rheumatoid arthritis four times less than the 2017 European infliximab market over a similar launch period.‘’
One of the main issues thought to be slowing the uptake of biosimilars in the US is biosimilar companies’ inability to provide competitive enough discounts to payers. Payers often have already negotiated volume-based discounts and other rebates with the company producing the reference product, making it difficult for biosimilars to compete.
‘’Even if a biosimilar is granted interchangeability status, if it ultimately cannot compete with the reference product on price, it will not be placed on a preferred tier.’’
For more information go to www.globaldata.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.